human breast cancer cell line mcf 7  (ATCC)

Journal: Biomolecules & Therapeutics

Article Title: Zoledronic Acid Inhibits the Growth of ER-Positive Breast Cancer Cells by Inducing Ferroptosis

doi: 10.4062/biomolther.2025.132

Figure Lengend Snippet: Zoledronic Acid Induces Ferroptosis in ER+ Breast Cancer Cells. (A) Dose-dependent growth inhibition by zoledronic acid (ZA). MCF-7 and ZR-75-1 cells were treated with increasing ZA concentrations (0-80 μM) for 72 h, followed by CCK-8 viability assays. (B) Intracellular iron accumulation quantified by colorimetric assay. Cells exposed to 40 μM ZA for 24 h showed elevated iron levels. (C, D) ZA-induced lipid peroxidation in MCF-7 (C) and ZR-75-1 (D) was detected by flow cytometry. Cells treated with 40 μM ZA for 24 h exhibited increased BODIPY 581/591 C11 oxidation. ** p <0.01; *** p <0.001.

Article Snippet: Human breast cancer cell lines MCF-7 (ATCC ® HTB-22TM), ZR-75-1 (ATCC ® CRL-1500TM), HCC1954, MDA-MB-231, and HEK293T-17 were obtained from the American Type Culture Collection (ATCC, MD, USA).

Techniques: Inhibition, CCK-8 Assay, Colorimetric Assay, Flow Cytometry

Journal: Biomolecules & Therapeutics

Article Title: Zoledronic Acid Inhibits the Growth of ER-Positive Breast Cancer Cells by Inducing Ferroptosis

doi: 10.4062/biomolther.2025.132

Figure Lengend Snippet: Ferrostatin-1 Attenuates ZA-Induced Ferroptosis. (A, B) Lipid ROS suppression by ferroptosis inhibition. Co-treatment with 5 μM Ferrostatin-1 (Ferro-1) partially reversed ZA-induced BODIPY 581/591 C11 oxidation in MCF-7 (A) and ZR-75-1 (B). (C) Viability rescue by Ferro-1. CCK-8 assays demonstrated partial recovery of cell growth in ZA (40 μM)+Ferro-1 (5 μM) co-treated groups after 48 h. * p <0.05; ** p <0.01; *** p <0.001.

Article Snippet: Human breast cancer cell lines MCF-7 (ATCC ® HTB-22TM), ZR-75-1 (ATCC ® CRL-1500TM), HCC1954, MDA-MB-231, and HEK293T-17 were obtained from the American Type Culture Collection (ATCC, MD, USA).

Techniques: Inhibition, CCK-8 Assay

Journal: Biomolecules & Therapeutics

Article Title: Zoledronic Acid Inhibits the Growth of ER-Positive Breast Cancer Cells by Inducing Ferroptosis

doi: 10.4062/biomolther.2025.132

Figure Lengend Snippet: Synergistic Ferroptosis Induction by ZA and RSL3. (A, B) Enhanced lipid peroxidation with combination therapy. RSL3 (5 μM) potentiated ZA-induced BODIPY 581/591 C11 oxidation in MCF-7 (A) and ZR-75-1 (B). (C) Cooperative growth inhibition. Crystal violet colony formation assay demonstrated ZA (40 μM)+RSL3 (5 μM) co-treatment for 6 days showed enhanced cytotoxicity compared to single agents. * p <0.05; ** p <0.01; *** p <0.001.

Article Snippet: Human breast cancer cell lines MCF-7 (ATCC ® HTB-22TM), ZR-75-1 (ATCC ® CRL-1500TM), HCC1954, MDA-MB-231, and HEK293T-17 were obtained from the American Type Culture Collection (ATCC, MD, USA).

Techniques: Inhibition, Colony Assay

Journal: Biomolecules & Therapeutics

Article Title: Zoledronic Acid Inhibits the Growth of ER-Positive Breast Cancer Cells by Inducing Ferroptosis

doi: 10.4062/biomolther.2025.132

Figure Lengend Snippet: ZA Downregulates Ferroptosis Suppressors SLC7A11 and GPX4. (A, B) Dose-dependent protein suppression. Western blot analysis revealed decreased SLC7A11 and GPX4 expression in MCF-7 (A) and ZR-75-1 (B) after 24 h ZA treatment (20-40 μM). Tubulin served as loading control.

Article Snippet: Human breast cancer cell lines MCF-7 (ATCC ® HTB-22TM), ZR-75-1 (ATCC ® CRL-1500TM), HCC1954, MDA-MB-231, and HEK293T-17 were obtained from the American Type Culture Collection (ATCC, MD, USA).

Techniques: Western Blot, Expressing, Control

Journal: Biomolecules & Therapeutics

Article Title: Zoledronic Acid Inhibits the Growth of ER-Positive Breast Cancer Cells by Inducing Ferroptosis

doi: 10.4062/biomolther.2025.132

Figure Lengend Snippet: ZA Activates Hippo Signaling Through YAP Regulation. (A) Phospho-YAP induction and total YAP reduction. Dose-responsive YAP phosphorylation and protein degradation in cells treated with ZA (20-40 μM) for 24 h. (B, C) Transcriptional downregulation of YAP targets. qRT-PCR showed decreased CTGF (B) and CYR61 (C) mRNA levels post-ZA treatment. (D) Accelerated YAP protein turnover. Cycloheximide (10 μM) chase assay demonstrated enhanced YAP degradation kinetics in MCF-7 cells pre-treated with 40 μM ZA. (E) YAP nuclear export. Immunofluorescence revealed dose-dependent reduction of nuclear YAP (green) in ZA-treated MCF-7 cells (8 h). Hoechst (blue) marks nuclei. Scale bar: 20 μm. ** p <0.01; *** p <0.001; ns: no significance.

Article Snippet: Human breast cancer cell lines MCF-7 (ATCC ® HTB-22TM), ZR-75-1 (ATCC ® CRL-1500TM), HCC1954, MDA-MB-231, and HEK293T-17 were obtained from the American Type Culture Collection (ATCC, MD, USA).

Techniques: Phospho-proteomics, Quantitative RT-PCR, Immunofluorescence

Journal: RSC Advances

Article Title: Rhenium-186-labeled ortho -hydroxythiobenzhydrazide: a potential theranostic agent for use in metastatic breast cancer

doi: 10.1039/d5ra07970e

Figure Lengend Snippet: (A): Cell binding, cell internalization and surface bound–[ 186 Re]Re-(htbh) 2 in MCF7 and Vero cell line; (B): MTT-based Cytotoxicity of H(htbh) and [ 186 Re]Re-(htbh) 2 in MCF7 and Vero cell line, showing comparative cell viability following pulsed treatment; Flow Cytometry-based detection of percentage sub G1 or dead cell population (DC) in (C): Control MCF 7 cells; and in treatment groups including (D): H(htbh); (E): [ 186 Re]Re-(htbh) 2 –Group 1; (F): [ 186 Re]Re-(htbh) 2 –Group 2. (G): Setting for live and dead cell selection using FSC and SSC plot; and (H): histogram showing percentage of dead cell population (DC) in different treatment groups.

Article Snippet: Human breast cancer cell line MCF7 (ATCC®, HTB-22TM) was used for in-vitro cell binding study for the evaluation of [ 186 Re]Re-(htbh) 2 complex.

Techniques: Binding Assay, Flow Cytometry, Control, Selection

Journal: RSC Advances

Article Title: Rhenium-186-labeled ortho -hydroxythiobenzhydrazide: a potential theranostic agent for use in metastatic breast cancer

doi: 10.1039/d5ra07970e

Figure Lengend Snippet: (A): Biodistribution of [ 186 Re]Re-(htbh) 2 in MCF-7 tumour xenografted female SCID mice; (B): tumour to organ ratio, 2 h post injection; (C and D): SPECT/CT images of female SCID mice with MCF7 tumour xenograft.

Article Snippet: Human breast cancer cell line MCF7 (ATCC®, HTB-22TM) was used for in-vitro cell binding study for the evaluation of [ 186 Re]Re-(htbh) 2 complex.

Techniques: Injection, Single Photon Emission Computed Tomography